SINOVAC Initiates Commercial Launch of its Adsorbed Tetanus Vaccine in China Following Regulatory Approval

2025-12-29

BEIJING, Dec. 29, 2025 – Sinovac Biotech Ltd. ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, recently announced the commercial launch of its self-developed Adsorbed Tetanus Vaccine. Developed and manufactured by the Company's subsidiary, Sinovac Life Sciences Co., Ltd., the first batch of the vaccine was shipped on December 26, 2025, following its approval by the National Medical Products Administration (NMPA) in August 2025.

The Adsorbed Tetanus Vaccine incorporates advancements in adjuvant formulation and purification processes. The formulation utilizes a nanoscale aluminum hydroxide adjuvant with a particle size of approximately 300 nanometers, which is designed to enhance antigen adsorption efficiency and formulation stability compared with conventional micron-scale adjuvants. In addition, optimization of the purification process is intended to further support the immunogenicity of the vaccine bulk. According to the results of a Phase III clinical study, the vaccine showed a superior Geometric Mean Concentration (GMC) compared with the control vaccine, while remaining a favorable safety profile.

Tetanus is an acute infectious disease caused by Clostridium tetani. Its case‑fatality rate approaches 100% without treatment and remains at 30–50% even with medical care. As a major global public health threat, tetanus causes an estimated 1 million cases and 300,000–500,000 deaths annually.¹ Although only 16,628 cases were reported globally in 2008, the actual annual number of cases is estimated to be between 500,000 and 1 million. ²Active immunization through vaccination is widely recognized as the most reliable and cost‑effective way to provide long‑lasting protection against tetanus.

The launch of the Adsorbed Tetanus Vaccine is a key component of SINOVAC's "Trauma Combination Products". In recent years, SINOVAC has accelerated the industrialization of multiple innovative products through strategic investments and global partnerships. These include Krebis^®, a Category 1 anti-rabies monoclonal antibody in China developed by Synermore Biologics with investment from SINOVAC, as well as a freeze-dried human rabies vaccine that has been selected for Brazil’s Productive Development Partnership (PDP) program, marking its entry into international public procurement channels.

SINOVAC remains committed to its mission to "Supply Vaccines to Eliminate Human Diseases". The Company continues to focus on accelerating vaccine R&D, optimizing manufacturing processes, and enhancing global accessibility to strengthen public health networks worldwide.

Reference:

1. Clinical Education of General Practice Jan. 2025, Vol.23, No.1, DOI：10.13558/j.cnki.issn1672-3686.2025.001.002

2. Chin J Surg, March 2018,Vol.56,No.3, DOI:10.3760/cma.j.issn.0529-5815.2018.03.001

About SINOVAC

Sinovac Biotech Ltd. (SINOVAC) is a China-based global biopharmaceutical company, with a mission of "supply vaccines to eliminate human diseases", the company specializes in the research, development, manufacturing and commercialization of vaccines and related biological products that protect against human infectious diseases.

The company's diversified portfolio includes vaccines for influenza, viral hepatitis, varicella, Hand-Foot-Mouth disease (HFMD), poliomyelitis, pneumococcal disease, etc., of which 3 vaccines have been prequalified by WHO, including inactivated hepatitis A vaccine Healive®, Sabin-strain inactivated polio vaccine (sIPV), and varicella vaccine.

SINOVAC has a leading edge in developing vaccines to combat infectious disease outbreaks and was among the first to initiate R&D during major public health emergencies, including SARS, H5N1, H1N1, and COVID-19. The company developed the world's first inactivated SARS vaccine (Phase I completed), China's first H5N1 influenza vaccine (Panflu®), the world's first H1N1 influenza vaccine (Panflu.1®), and CoronaVac®, the most widely used inactivated COVID-19 vaccine globally.

Beyond its marketed portfolio, the company is advancing a robust pipeline that includes combination vaccines, recombinant protein vaccines and next-generation platforms such as mRNA technologies and antibodies.

With a long-standing commitment to innovation and global health, SINOVAC is expanding its global footprint by strengthening partnerships with research institutions, international organizations, and local partners. Through broader market presence, technological cooperation, and localized production, the company aims to accelerate vaccine development and supply, enhance regional access to high-quality products, and better address unmet medical needs while improving preparedness for future pandemics.

For more information, please see the Company’s website at www.sinovac.com.